Tero Aittokallio

Tero Aittokallio serves as a Senior Researcher at the Finnish Institute of Molecular Medicine (FIMM) within the University of Helsinki's Faculty of Medicine, where he holds multiple doctoral program supervision roles across Biomedicine, Clinical Research, Drug Research, and Integrative Life Science. His academic foundation includes a PhD in Applied Mathematics from the University of Turku (2001) and a concurrent position as Professor of Statistics and Applied Mathematics at the same institution since 2015.

His research spans bioinformatics, computational biology, and machine learning applications in drug discovery, with particular focus on cancer therapeutics, systems pharmacology, and precision medicine. Current work emphasizes AI-driven prediction of drug combinations for leukemia and lymphoma treatment, computational drug repurposing, and high-throughput screening methodologies. His publication trends reveal increasing specialization in machine learning applications for oncology since 2020, with recent articles in high-impact journals like Nature Reviews Drug Discovery and Blood.

Awarded the Helsinki Challenge in 2017, his work has generated significant media attention including 27 visibility items between 2020-2025, notably for AI models predicting cancer-killing drug combinations. He leads 7 active research projects totaling over €2 million in funding from diverse sources including the European Commission (REMEDI4ALL), Sigrid Jusélius Foundation, Cancer Foundation, and University of Copenhagen.

His supervisory activities include 13 academic events comprising doctoral thesis examinations, co-supervision of dissertations, and international academic visits. Current projects address chronic lymphocytic leukemia treatment optimization, multi-targeted drug discovery, and NK-cell cytotoxicity enhancement in leukemia, reflecting his commitment to translating computational approaches into clinical oncology applications.